A phase 1 study of BPI-002, an oral CTLA-4 inhibitor in Cancer.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs BPI 002 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 06 Apr 2018 New trial record
- 03 Apr 2018 According to a BeyondSpring Pharmaceuticals media release, company plans this study in 2019.